CarolLaceyPA

PubMed

• 6 citations
  GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report.
  Sapna Pradyuman Patel, Dae Won Kim, Carol Lacey, Patrick Hwu> ;Medicine. 2016 Jan 1
• 23 citations
  Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report
  Isabella C. Glitza, Cara Haymaker, Chantale Bernatchez, Luis M Vence, Michelle Rohlfs, Jessie Richard, Carol Lacey, Rahmatu Mansaray, Orenthial J. Fulbright, Renjith R...> ;Cancer Immunology Research. 2015 Nov 1
• 167 citations
  IL-2 therapy promotes suppressive ICOS + Treg expansion in melanoma patients
  Geok Choo Sim, Natalia Martin-Orozco, Lei Jin, Yan Yang, Sheng Wu, Edwina Washington, Deborah Sanders, Carol Lacey, Yijun Wang, Luis M Vence, Patrick Hwu, Laszlo Radvanyi> ;The Journal of Clinical Investigation. 2014 Jan 2
• 20 citations
  Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
  Doina Ivan, Maria Niveiro, A. Hafeez Diwan, Omar Eton, Kevin B. Kim, Carol Lacey, Cipriano Gonzalez, Victor G. Prieto> ;Journal of Cutaneous Pathology. 2006 Apr 1
• Join now to see all

Journal Articles

• Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results  
  Isabella Glitza, et al, Nature Medicine, 3/30/2023
• Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2  
  Isabella Glitza, et al., ESMO, 1/1/2019
• THERAPEUTIC OUTCOMES OF INTRATHECAL INTERLEUKIN-2 IN METASTATIC MELANOMA PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD)  
  Isabella Glitza, et al, Neuro-Oncology, Volume 17, Issue suppl_5, 1 November 2015, Page v108,, 11/9/2015
• Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, GleevecTM)  
  Doina Ivan, et al., Journal of Cutaneous PathologyVolume 33, Issue 4, 3/29/2006
• Join now to see all

Abstracts/Posters

• BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma.
  M. Rohlfs et al, Journal of Clinical Oncology 2016 34:15_suppl, 9548-9548, 5/15/2016